HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib.

AuthorsLisa Pieri, Alessandro Pancrazzi, Annalisa Pacilli, Claudia Rabuzzi, Giada Rotunno, Tiziana Fanelli, Paola Guglielmelli, Rajmonda Fjerza, Chiara Paoli, Srdan Verstovsek, Alessandro M Vannucchi
JournalBlood (Blood) Vol. 125 Issue 21 Pg. 3352-3 (May 21 2015) ISSN: 1528-0020 [Electronic] United States
PMID25999444 (Publication Type: Clinical Trial, Phase II, Letter, Research Support, Non-U.S. Gov't)
Chemical References
  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • ruxolitinib
  • JAK2 protein, human
  • Janus Kinase 2
Topics
  • Humans
  • Janus Kinase 2 (genetics)
  • Nitriles
  • Polycythemia Vera (drug therapy, genetics)
  • Pyrazoles (therapeutic use)
  • Pyrimidines
  • Reverse Transcriptase Polymerase Chain Reaction
  • Thrombocythemia, Essential (drug therapy, genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: